Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026
The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version...
CSPC Pharmaceutical
CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...
Novartis Defends Entresto Patents as Generic Approvals Trigger Legal Response
On August 24, 2023, generic versions of Novartis’ (NYSE: NVS) heart failure therapy Entresto (sacubitril,...
CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss...
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma
Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent
The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...
Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...
Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction
Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...
CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...
CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...